Efficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis
Bonnie W. Ramsey(Seattle Children's Hospital), Arnold L. Smith(Seattle Children's Hospital), Richard M. Kravitz(University of Cincinnati), Henry L. Dorkin(Boston Children's Hospital), Ronald L. Gibson(Seattle Children's Hospital), Kim R. Wentz(University of Washington), Jay D. Eisenberg(Oregon Health & Science University), Robert W. Wilmott(University of Toledo), Daniel V. Schidlow(Temple University), Mary Ann McBurnie(Unknown), Ivan R. Harwood(University of California San Diego), Susan J. Astley(Jikei University School of Medicine)
Cited by 455
Related Papers
Frailty in Older Adults: Evidence for a Phenotype
|The Journals of Gerontology Series A|2001|24.4k
International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study
|The Lancet|2007|2.4k
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
|New England Journal of Medicine|1999|1.3k
Associations of Subclinical Cardiovascular Disease With Frailty
|The Journals of Gerontology Series A|2001|817